NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
NewsRx | Free Newsletters
 
----------
------------
NewsRx on Facebook
-----
NewsRx Passes
Press Release Submissions
PR Login
-----
2008 Award Logo
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
-----
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.

Security by Verisign

Malaria Vaccine


Return to Library

Free Malaria Vaccine Articles


New findings from J. Krucken and co-researchers in the area of immunization described



2009 JUL 13 - (NewsRx.com) -- Researchers in Hannover, Germany conducted a study "To date all efforts to develop a malaria vaccine have failed, reflecting the still fragmentary knowledge about protective mechanisms against malaria. In order to evaluate if vaccination changes responses of the anti-malaria effectors spleen and liver to blood stage malaria, BALB/c mice succumbing to infection with Plasmodium chabaudi were compared to those surviving after vaccination."

"Mice were vaccinated with host cell plasma membranes isolated from P. chabaudi-infected erythrocytes. Hepatic and splenic capacity to trap particulate material was determined after injection of fluorescent polystyrol beads. Hepatic gene expression was measured using real-time RT-PCR and Northern blotting. Survival of BALB/c mice was raised from 0% to 80% and peak parasitaemia was decreased by about 30% by vaccination. Vaccination boosted particle trapping capacity of the liver during crisis when splenic trapping is minimal due to spleen 'closing'. It also attenuated malaria-induced inflammation, thus diminishing severe damages and hence liver failure. Vaccination increased hepatic IFN-gamma production but mitigated acute phase response. Vaccination has a complex influence on infection-induced changes in expression of hepatic nuclear receptors (CAR, FXR, RXR, and PXR) and of the metabolic enzymes Sult2a and Cyp7a1. Although vaccination decreased CAR mRNA levels and prevented Cyp7a1 suppression by the CAR ligand 1,2-bis [2-(3,5dichloropyridyloxy)] benzene (TCPOBOP) on day 8 p.i., Sult2a-induction by TCPOBOP was restored," wrote J. Krucken and colleagues.

The researchers concluded: "These data support the view that the liver is an essential effector site for a vaccine against blood stage malaria: vaccination attenuates malaria-induced inflammation thus improving hepatic metabolic activity and particle trapping activity of the liver."

Krucken and colleagues published the results of their research in Malaria Journal (Augmented particle trapping and attenuated inflammation in the liver by protective vaccination against Plasmodium chabaudi malaria. Malaria Journal, 2009;8():54).

For additional information, contact J. Krucken, University of Vet. Med Foundation, Institute Parasitology, Bunteweg 17, Hannover, Germany.

The publisher of the Malaria Journal can be contacted at: Biomedical Central Ltd., Current Science Group, Middlesex House, 34-42 Cleveland St., London W1T 4LB, England.

Keywords: Germany, Hannover, Biotechnology, Immunization, Inflammation, Malaria Vaccines, Vaccination.

This article was prepared by Malaria Weekly editors from staff and other reports. Copyright 2009, Malaria Weekly via NewsRx.com.

NewsRx NewsRx NewsRx
-----------------------
PR Login